The 21-gene Recurrence Score® assay predicts distant recurrence in lymph node-positive, hormone receptor-positive, breast cancer patients treated with adjuvant sequential epirubicin- and docetaxel-based or epirubicin-based chemotherapy (PACS-01 trial).

Date publication

mai 2018

Journal

BMC cancer

Auteurs

Membres identifiés du Cancéropôle Est :
Pr FUMOLEAU Pierre

Tous les auteurs :
Penault-Llorca F, Filleron T, Asselain B, Baehner FL, Fumoleau P, Lacroix-Triki M, Anderson JM, Yoshizawa C, Cherbavaz DB, Shak S, Roca L, Sagan C, Lemonnier J, Martin AL, Roché H

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/29728098

Résumé

The 21-gene Recurrence Score (RS) result predicts outcome and chemotherapy benefit in node-negative and node-positive (N+), estrogen receptor-positive (ER+) patients treated with endocrine therapy. The purpose of this study was to evaluate the prognostic impact of RS results in N+, hormone receptor-positive (HR+) patients treated with adjuvant chemotherapy (6 cycles of FEC100 vs. 3 cycles of FEC100 followed by 3 cycles of docetaxel 100 mg/m) plus endocrine therapy (ET) in the PACS-01 trial (J Clin Oncol 2006;24:5664-5671).

Mots clés

Adjuvant chemotherapy, Breast cancer, Docetaxel, Epirubicin, Hormone receptor-positive, Lymph node-positive, Oncotype DX® 21-gene assay, Recurrence score® result, Tamoxifen

Référence

BMC Cancer. 2018 05 4;18(1):526